Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 And 4.0 Ng./Ml.

Journal of Urology

Volumn 165, Issue 6 I, 2001, Pages

  Okihara, K ^a   Fritsche, H A ^a   Ayala, A ^a   Johnston, D A ^a   Allard, W J ^a   Babaian, R J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biopsy; Prostate; Prostate specific antigens; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CALCULATION; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; BLOOD; ENZYME IMMUNOASSAY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; STATISTICAL MODEL;

ADULT; AGED; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0034981586     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66245-3     Document Type: Article

References (27)

1. Measurement of PSA in serum as a screening test for prostate cancer
2. Screening for prostatic carcinoma with prostate specific antigen
3. Screening for prostatic carcinoma with prostate specific antigen: Results of the second year
4. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements
5. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men
6. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer
7. Longitudinal screening for prostate cancer with prostate-specific antigen
8. Prostate cancer detection at low prostate specific antigen
9. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model
10. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
11. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
12. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
13. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
14. Determination of alphalantichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
15. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
16. Optimization of prostate biopsy strategy using computer based analysis
17. The performance of a neural network in detecting prostate cancer in the PSA reflex range of 2.5-4.0 ng/ml
18. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer
19. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml
20. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age
21. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?
22. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia
23. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer
24. Prostate-specific antigen in serum occurs predominantly in complex with a-1-antichymotrypsin
25. Measurement of complexed PSA improves specificity for early detection of prostate cancer
26. Measurement of the complex between prostate-specific antigen and αl-protease inhibitor in serum
27. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer